Understanding a protein called eIF5B in lung cancer
The role of translation initiation factor eIF5B in lung cancer pathogenesis
This research explores how a specific protein called eIF5B contributes to lung cancer and its resistance to current immune therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-11109674 on NIH RePORTER |
What this research studies
Many lung cancer patients do not fully benefit from current immune therapies that target PD-L1, a protein that helps cancer cells hide from the immune system. We found that a protein called eIF5B can increase PD-L1 levels in lung cancer cells, even without other triggers. This suggests eIF5B might be a key player in how lung cancer evades the immune system. By understanding how eIF5B works, we hope to find new ways to make immune therapies more effective for more patients.
Who could benefit from this research
Good fit: This foundational research is relevant for all patients with non-small cell lung cancer, particularly those whose tumors express high levels of PD-L1 or do not respond well to current immunotherapy.
Not a fit: Patients with cancers other than lung cancer or those whose tumors do not involve the PD-L1 pathway may not directly benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to new treatment strategies or drug targets for lung cancer, especially for patients who do not respond to existing immune checkpoint therapies.
How similar studies have performed: This research has uncovered a new mechanism of immune checkpoint activation, suggesting a novel and untested approach to targeting lung cancer.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: O'donnell, Kathryn Ann — Ut Southwestern Medical Center
- Study coordinator: O'donnell, Kathryn Ann
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.